Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 2/20 | 0.46 |
| ▸ | ACACB | O00763 | 9/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL313677 | 0.97 | ITGB3 (0.48) | ITGB3ITGA2BMEN1ALDH1A1LMNA | |
| SCHEMBL313030 | 0.93 | MEN1 (0.54) | ITGB3ITGA2BMEN1ALDH1A1LMNA | |
| SCHEMBL1857477 | 0.89 | ALDH1A1 (0.50) | ITGB3ITGA2BMEN1ALDH1A1LMNA | |
| SCHEMBL315157 | 0.87 | MEN1 (0.51) | MEN1ALDH1A1LMNAKMT2AGAA | |
| SCHEMBL313634 | 0.86 | TACR1 (0.51) | ALDH1A1KMT2ATACR1 | |
| SCHEMBL313678 | 0.86 | TSHR (0.44) | ITGB3ITGA2BMEN1ALDH1A1LMNA | |
| SCHEMBL1862350 | 0.81 | MEN1 (0.61) | MEN1ALDH1A1LMNAKMT2AGAA | |
| SCHEMBL313537 | 0.81 | MEN1 (0.58) | MEN1ALDH1A1LMNAKMT2AGAA | |
| SCHEMBL2619550 | 0.81 | MEN1 (0.58) | MEN1ALDH1A1LMNAKMT2AGAA | |
| SCHEMBL1858694 | 0.79 | ALDH1A1 (0.56) | ITGB3ITGA2BMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664426-B2 | Functionalized amino acids and absorbable polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664426-B2 | Functionalized amino acids and absorbable polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664426-B2 | Functionalized amino acids and absorbable polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2014-03-04 | — | — | US | disclosed |
| EP-1948713-B1 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | BEZWADA BIOMEDICAL LLC (US) | 2013-12-04 | — | — | EP | disclosed |
| US-20130317118-A1 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2013-11-28 | — | — | US | disclosed |
| US-8519175-B2 | Functionalized amino acids and absorbable polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2013-08-27 | — | — | US | disclosed |
| US-8519175-B2 | Functionalized amino acids and absorbable polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2013-08-27 | — | — | US | disclosed |
| US-8519175-B2 | Functionalized amino acids and absorbable polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130030061-A1 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130030061-A1 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20120094994-A1 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2012-04-19 | — | — | US | disclosed |
| US-8093420-B2 | Functionalized amino acids and absorbable polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093420-B2 | Functionalized amino acids and absorbable polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093420-B2 | Functionalized amino acids and absorbable polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090098180-A1 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090098180-A1 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090098180-A1 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2009-04-16 | — | — | US | disclosed |
| EP-1948713-A2 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | Bezwada Biomedical LLC (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007047244-A2 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | BEZWADA BIOMEDICAL LLC (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047244-A2 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | BEZWADA BIOMEDICAL LLC (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098180-A1 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | BCAT2, BCAT1, SLC7A1 | ITGB3 1662/4885ITGA2B 1158/4885MEN1 2243/4885 |
| US-20120094994-A1 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | BCAT2, BCAT1, SLC7A1 | ITGB3 1662/4885ITGA2B 1158/4885MEN1 2243/4885 |
| US-20130030061-A1 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | BCAT2, BCAT1, SLC7A1 | ITGB3 1662/4885ITGA2B 1158/4885MEN1 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.